Literature DB >> 22061824

A specific protein disorder catalyzer of HIV-1 Nef.

Adrien Lugari1, Sebastian Breuer, Thibault Coursindel, Sandrine Opi, Audrey Restouin, Xiaoli Shi, Alexis Nazabal, Bruce E Torbett, Jean Martinez, Yves Collette, Isabelle Parrot, Stefan T Arold, Xavier Morelli.   

Abstract

The HIV-1 auxiliary protein Nef is required for the onset and progression of AIDS in HIV-1-infected persons. Here, we have deciphered the mode of action of a second-generation inhibitor of Nef, DLC27-14, presenting a competitive IC(50) of ∼16 μM measured by MALDI-TOF experiments. Thermal protein denaturation experiments revealed a negative effect on stability of Nef in the presence of a saturating concentration of the inhibitor. The destabilizing action of DLC27-14 was confirmed by a HIV protease-based experiment, in which the protease sensitivity of DLC27-14-bound Nef was three times as high as that of apo Nef. The only compatible docking modes of action for DLC27-14 suggest that DLC27-14 promotes an opening of two α-helices that would destabilize the Nef core domain. DLC27-14 thus acts as a specific protein disorder catalyzer that destabilizes the folded conformation of the protein. Our results open novel avenues toward the development of next-generation Nef inhibitors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22061824     DOI: 10.1016/j.bmc.2011.10.051

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  Small molecule inhibitors of the HIV-1 virulence factor, Nef.

Authors:  Thomas E Smithgall; Gary Thomas
Journal:  Drug Discov Today Technol       Date:  2013-12

2.  A Biochemical/Biophysical Assay Dyad for HTS-Compatible Triaging of Inhibitors of the HIV-1 Nef/Hck SH3 Interaction.

Authors:  Sebastian Breuer; Sheryll Espinola; Xavier Morelli; Bruce E Torbett; Stefan T Arold; Ingo H Engels
Journal:  Curr Chem Genom Transl Med       Date:  2013-07-26

Review 3.  Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor.

Authors:  Lori A Emert-Sedlak; Haibin Shi; Colin M Tice; Li Chen; John J Alvarado; Sherry T Shu; Shoucheng Du; Catherine E Thomas; Jay E Wrobel; Allen B Reitz; Thomas E Smithgall
Journal:  Viruses       Date:  2022-09-13       Impact factor: 5.818

4.  Discovery of a diaminoquinoxaline benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screen.

Authors:  Ronald P Trible; Purushottam Narute; Lori A Emert-Sedlak; John Jeff Alvarado; Katelyn Atkins; Laurel Thomas; Toshiaki Kodama; Naveena Yanamala; Vasiliy Korotchenko; Billy W Day; Gary Thomas; Thomas E Smithgall
Journal:  Retrovirology       Date:  2013-11-14       Impact factor: 4.602

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.